

Bacterial and Viral Vectors as Vaccine Delivery Vehicles in the Treatment of Breast Cancer

Wenjie Hung*

Vaccine Research Institute Science and Technology, China

Abstract

Breast most cancers is the often identified most cancers amongst ladies and it is the most deadly malignancy in ladies globally. With one million instances each and every year, breast most cancers is the fast-growing most cancers kind that has an excessive incidence fee in younger women. The boundaries and undesirable aspect outcomes of traditional treatments like chemotherapy and radiotherapy on malignant tumors necessitate the improvement of choice therapeutic approaches. Gene remedy has emerged as a promising method to therapy a range of malignant most cancers kinds which includes the shipping of practical gene immediately into the goal tumor tissue. Efficient gene remedy method depends on the high quality transport of therapeutic genes to the favored phone type. In this regard, organic and non-biological gene shipping vectors are used to defend the bare overseas DNA to mediate high-quality tissue entry of the preferred gene of interest. In this review, the use of bacterial and viral vectors for breast most cancers gene remedy used to be summarized.

Keywords: Breast Cancer; Anti-tumor therapy; Personalized medicine; Surgery; Adjuvant therapies; Chemotherapy; Hormone therapy

Introduction

Breast cancer is a complex and challenging disease that affects millions of individuals worldwide, making it one of the most prevalent forms of cancer among women. While advancements in treatment modalities, such as surgery, chemotherapy, radiation therapy, and targeted therapies, have improved patient outcomes over the years, there remains a pressing need for innovative and effective strategies to combat this formidable foe. Recent developments in the field of cancer immunotherapy have brought forth promising avenues for the treatment of breast cancer, and one such approach involves the use of bacterial and viral vectors as vaccine delivery vehicles. Cancer immunotherapy harnesses the body's own immune system to recognize and attack cancer cells, offering a unique and potentially potent alternative to traditional cancer treatments. Among the various immunotherapeutic strategies, cancer vaccines have emerged as a particularly appealing approach. These vaccines are designed to stimulate the immune system to recognize and mount a specific response against cancer cells, thereby enhancing the body's ability to combat the disease. Bacterial and viral vectors have garnered considerable attention in recent years as valuable tools for delivering cancer vaccines [1,2]. These vectors, derived from naturally occurring microorganisms, possess unique properties that make them well-suited for vaccine delivery. Bacteria and viruses can be engineered to carry tumor-associated antigens, which are molecules specific to cancer cells, and when administered to patients, they stimulate the immune system to target these antigens [3]. This targeted immune response holds significant promise for the treatment of breast cancer, as it offers the potential to eradicate cancer cells while sparing healthy tissue and minimizing the side effects commonly associated with conventional therapies. In this review, we will explore the use of bacterial and viral vectors as vaccine delivery vehicles in the context of breast cancer treatment. We will delve into the underlying principles of these vectors, their mechanisms of action, and the exciting progress made in preclinical and clinical studies. Additionally, we will discuss the challenges and considerations associated with the use of these vectors in cancer immunotherapy, including safety concerns and strategies to enhance their efficacy. The integration of bacterial and viral vectors into

breast cancer immunotherapy represents a promising frontier in the ongoing battle against this devastating disease. As researchers continue to uncover the full potential of these innovative vaccine delivery systems, there is a growing optimism that they may play a pivotal role in improving treatment outcomes and enhancing the quality of life for breast cancer patients. This review aims to provide a comprehensive overview of the current state of research in this field and to shed light on the future prospects of bacterial and viral vectors as valuable allies in the fight against breast cancer [4,5].

Discussion

Certainly, let's delve deeper into the discussion of anti-tumor therapy for breast cancer. Breast cancer is a heterogeneous disease with various subtypes, and the choice of therapy depends on the specific characteristics of the tumor, its stage, and the patient's overall health. Here are some key points to consider in the discussion of breast cancer treatment:

Personalized medicine

The field of breast cancer treatment has seen significant advancements in personalized medicine. Understanding the molecular and genetic characteristics of the tumor, including hormone receptor status (ER, PR), HER2/new status, and genetic mutations (e.g., BRCA1/2), is crucial in tailoring therapy. This allows for targeted therapies that can improve treatment efficacy and minimize side effects.

Surgery's role

Surgical interventions, such as lumpectomy and mastectomy, are

*Corresponding author: Wenjie Hung, Vaccine Research Institute Science and Technology, China, E-mail: whung@mail.edu.cn

Received: 01-Oct-2023, Manuscript No: bccr-23-117060; **Editor assigned:** 03-Oct-2023, Pre-QC No: bccr-23-117060 (PQ); **Reviewed:** 17-Oct-2023, QC No: bccr-23-117060; **Revised:** 23-Oct-2023, Manuscript No: bccr-23-117060 (R); **Published:** 30-Oct-2023, DOI: 10.4172/2572-4118.1000210

Citation: Hung W (2023) Bacterial and Viral Vectors as Vaccine Delivery Vehicles in the Treatment of Breast Cancer. Breast Can Curr Res 8: 210.

Copyright: © 2023 Hung W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

often the primary treatment for localized breast cancer. Advances in surgical techniques and reconstruction options have improved the quality of life for many patients [6].

Adjuvant therapies

In addition to surgery, adjuvant therapies like radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy play pivotal roles in treating breast cancer. They can help eliminate remaining cancer cells, reduce the risk of recurrence, and improve survival rates.

Chemotherapy and hormone therapy

Chemotherapy is used in various scenarios, including neoadjuvant (pre-surgery) and adjuvant settings. Hormone therapy, particularly for hormone receptor-positive tumors, has been a game-changer in breast cancer management, preventing cancer recurrence and extending survival [7].

Targeted and immunotherapies

Targeted therapies like Herceptin for HER2-positive breast cancer and PARP inhibitors for BRCA-mutated cancers have improved outcomes. Immunotherapy is also a promising avenue, with ongoing research into its potential for breast cancer treatment.

Treatment sequencing

The order and combination of therapies can vary. For example, some patients may receive chemotherapy before surgery to shrink tumors, while others may receive it after surgery to prevent recurrence [8].

Side effects and quality of life

Breast cancer treatments can have side effects that impact a patient's quality of life. These may include fatigue, nausea, hair loss, and emotional distress. Managing side effects and providing supportive care are crucial aspects of treatment.

Survivorship care

The long-term follow-up and monitoring of breast cancer survivors are essential to detect recurrence or late side effects early and address survivors' ongoing physical and emotional needs

Emerging therapies

Clinical trials are continually exploring new treatments, including novel drugs, combination therapies, and innovative approaches like gene therapy and nanomedicine.

Psychosocial support

Breast cancer treatment can be physically and emotionally challenging. Providing psychosocial support through counseling, support groups, and survivorship programs is integral to the holistic care of breast cancer patients.

Health equity

Ensuring access to appropriate breast cancer treatment for all populations, regardless of socioeconomic status, race, or geography, is a critical consideration in breast cancer care.

Patient-centered care

Patient preferences and shared decision-making between patients

and healthcare providers are increasingly emphasized to tailor treatments to individual needs and values [9,10].

Conclusion

In conclusion, breast cancer treatment has evolved significantly over the years, with a focus on personalized and targeted therapies. A multidisciplinary approach that combines surgery, radiation, chemotherapy, hormone therapy, targeted therapy, and immunotherapy is often employed to effectively combat this complex disease. The choice of treatment depends on the specific characteristics of the tumor, including hormone receptor status, HER2/new status, and genetic mutations, as well as the stage of the cancer and the patient's overall health. Advancements in personalized medicine have allowed for the tailoring of treatments to individual patients, resulting in improved outcomes and minimized side effects. The development of targeted therapies, such as Herceptin and PARP inhibitors, has revolutionized the management of breast cancer, offering more precise and effective options for certain subtypes. Immunotherapy is a promising frontier, with ongoing research into checkpoint inhibitors and other immunotherapeutic approaches. These therapies aim to harness the patient's own immune system to recognize and attack cancer cells, potentially providing long-term benefits. Supportive care, including psychosocial support and survivorship programs, is integral to addressing the physical and emotional needs of breast cancer patients throughout their journey. While challenges remain, including managing treatment-related side effects and ensuring equitable access to care, the outlook for breast cancer patients has improved significantly. Ongoing clinical trials and research into novel therapies, including cancer vaccines and innovative delivery methods, offer hope for continued progress in the fight against breast cancer. Ultimately, the goal is not only to treat breast cancer effectively but also to enhance the quality of life for patients, promote survivorship, and work towards a future where breast cancer is more manageable and, ultimately, preventable. The collaborative efforts of healthcare professionals, researchers, and patients themselves are crucial in achieving this objective.

Conflict of Interest

None

Acknowledgment

None

References

- Li X, Ma F, Yang M, Zhang J, (2022) Nanomaterial Based Analytical Methods for Breast Cancer Biomarker Detection. *Mater. Today Adv* 14: 100219.
- Sung H, Ferlay J, Siegel R.L, Laversanne M, Soerjomataram I, et.al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Ca Cancer J Clin* 71: 209-249.
- Kindts I, Laenen A, Depuydt T, Weltens C (2017) Tumour bed boost radiotherapy for women after breast conserving surgery. *Cochrane Database Syst Rev* 11: CD011987.
- Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, et.al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet* 390: 1048-1060.
- Chinen AB, Guan CM, Jennifer JR, Barnaby SN, Merkel TJ, et.al (2015) Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. *Chem Rev* 115: 10530-10574.
- Azzouz A, Hejji L, Kim K-H, Kukkar D, Souhail B, et.al (2022) Advances in Surface Plasmon Resonance-Based Biosensor Technologies for Cancer Biomarker Detection. *Biosens Bioelectron* 197: 113767

7. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, et al. (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. *JAMA* 318: 918-926.
8. Koulis TA, Phan T, Olivetto IA (2015) Hypofractionated whole breast radiotherapy: current perspectives. *Breast Cancer (Dove Med Press)* 7: 363-370.
9. Ulucan-Karnak F, Akgöl S (2021) A New Nanomaterial Based Biosensor for MUC1 Biomarker Detection in Early Diagnosis, Tumor Progression and Treatment of Cancer. *Nanomanufacturing* 1: 14-38
10. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, et al. (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. *Lancet* 395: 1613-1626.